drug
clevidipine
Marketedupdated 3mo agoby Chiesi USA Inc
Approvedcommunity read0 votes
indications
investigational
Hypertension
all catalysts(0)
nothing on the calendar yet
Trials studying clevidipine
- —Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
- phase4Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
- phase3a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 10, 2031
~5.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Oct 10, 2031formulationUS 10010537
- Oct 10, 2031formulationUS 10010537
- Oct 10, 2031formulationUS 10010537
- Oct 10, 2031formulationUS 11103490
- Oct 10, 2031formulationUS 11103490
- Oct 10, 2031formulationUS 11103490
- Oct 10, 2031formulationUS 8658676
- Oct 10, 2031formulationUS 8658676
- Oct 10, 2031formulationUS 8658676
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that